Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP1189 in early rheumatoid arthritis
2019-001185-15Phase 2Completed
- Sponsor
- SynAct Pharma AB
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing AP1189 with Placebo (2 arms). Primary endpoint: Primary safety endpoint. Started Apr 2019; status: completed.
02
Drugs
resomelagon
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2019-001185-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001185-15.